Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens
From MaRDI portal
Publication:6628011
DOI10.1002/SIM.9113zbMATH Open1546.62252MaRDI QIDQ6628011
Could not fetch data.
Publication date: 29 October 2024
Published in: Statistics in Medicine (Search for Journal in Brave)
pharmacokinetics/pharmacodynamicsdose regimenearly phase oncologyBayesian joint modelingbivariate toxicitycumulative probability of toxicity
Could not fetch data.
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Adaptive designs for dose-finding based on efficacy-toxicity response
- A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients
- Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes
- Optimal designs for copula models
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
- Design and Analysis of Phase I Clinical Trials
- Continual reassessment method with multiple toxicity constraints
- Determining the Effective Sample Size of a Parametric Prior
- Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations
- Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
- Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
- A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules
- Bayesian optimal interval designs for phase I clinical trials
Related Items (1)
This page was built for publication: Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6628011)
